Morgan Stanley
AMLX icon

Morgan Stanley’s Amylyx Pharmaceuticals AMLX Stock Holding History

Morgan Stanley’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.2M Buy
3,130,808
+955,261
+44% +$14.8M ﹤0.01% 2110
2026
Q1 		$30.2M Sell
2,175,547
-184,277
-8% -$2.59M ﹤0.01% 2568
2025
Q4 		$28.5M Buy
2,359,824
+409,523
+21% +$5.56M ﹤0.01% 2612
2025
Q3 		$26.5M Buy
1,950,301
+1,463,408
+301% +$13.8M ﹤0.01% 2611
2025
Q2 		$3.12M Buy
486,893
+12,475
+3% +$60.7K ﹤0.01% 4420
2025
Q1 		$1.68M Buy
474,418
+10,198
+2% +$36.3K ﹤0.01% 4716
2024
Q4 		$1.75M Sell
464,220
-14,045
-3% -$66.1K ﹤0.01% 4795
2024
Q3 		$1.55M Sell
478,265
-446,194
-48% -$1M ﹤0.01% 4793
2024
Q2 		$1.76M Sell
924,459
-1,146,194
-55% -$2.22M ﹤0.01% 4645
2024
Q1 		$5.88M Sell
2,070,653
-759,590
-27% -$9.93M ﹤0.01% 3793
2023
Q4 		$41.7M Buy
2,830,243
+1,878,124
+197% +$28.8M ﹤0.01% 1925
2023
Q3 		$17.4M Sell
952,119
-99,727
-9% -$2.11M ﹤0.01% 2613
2023
Q2 		$22.7M Buy
1,051,846
+149,299
+17% +$4.03M ﹤0.01% 2352
2023
Q1 		$26.5M Buy
902,547
+418,078
+86% +$14.5M ﹤0.01% 2129
2022
Q4 		$17.9M Buy
484,469
+215,399
+80% +$7.64M ﹤0.01% 2453
2022
Q3 		$7.58M Buy
269,070
+225,964
+524% +$5.64M ﹤0.01% 3261
2022
Q2 		$829K Buy
43,106
+761
+2% +$9.04K ﹤0.01% 5133
2022
Q1 		$544K Buy
+42,345
New +$956K ﹤0.01% 5356

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Morgan Stanley's AMLX Position: Q2 2026 in Review

Morgan Stanley increased its Amylyx Pharmaceuticals (AMLX) stake by 44% in Q2 2026, buying an estimated $14.8M and bringing the position to 3,130,808 shares worth $56.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2110.

Morgan Stanley first reported a position in AMLX in Q1 2022 and has held it in 18 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Morgan Stanley held 3,130,808 shares of Amylyx Pharmaceuticals worth $56.2M as of Q2 2026.
  • Morgan Stanley bought 955,261 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $14.8M.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2110 holding.
  • Morgan Stanley first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.